Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...

As Chair of the Scientific Advisory Committee, Dr. Lewis-Hall will provide leadership in scientific, clinical, and regulatory governance across Helus' portfolio, advising on discovery opportunities, ...

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and ...

Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsAndrew Guggenhime - President & CFOGrant Pickering ...

WHAT: University Health Network (UHN) will host a special in-person celebration recognizing a significant international milestone for the organization. The event reflects UHN's growing global impact ...

Over the years, Oyeyinka has served in several high-level policy and academic roles, including as Senior Special Adviser on ...

Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value CatalystsMarket News Updates News ...

"Devyn brings a rare combination of scientific depth, operational leadership, and strategic perspective," said Nazli Azimi, Ph.D., Chief Executive Officer of Therna. "His experience across genetic ...

Dr. Paul Bunge begins his new book about COVID-19 by inviting readers to join him on a journey — one he knows will be uncomfortable, perhaps even full of disagreements. Bunge, a former U.S.

Novo Nordisk announces plan to cut Ozempic and Wegovy prices up to 50 percent - One in eight Americans are taking weight loss drugs like Ozempic and Wegovy ...

The Hormone Replacement Therapy (HRT) market is poised to expand significantly from $23.58 billion in 2025 to $38.18 billion ...

Children with multiple nut allergies experienced significant increases in the amounts of allergens they could tolerate with ...